Furthermore, and in contrast to the traditional tumor marker CEA, our amplicon sequencing assay for cfDNA analysis could also reveal biological insights into the mechanisms of therapy resistance to targeted therapies. The gene discussed is CEACAM5; the disease is neoplasm.